These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 1800381)

  • 1. Interpretive criteria of antimicrobial disk susceptibility tests with cefpodoxime.
    Grimm H
    Infection; 1991; 19(5):380-2. PubMed ID: 1800381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary interpretive susceptibility testing criteria for FK-037 with 30-microgram disks.
    Jones RN
    J Clin Microbiol; 1994 Apr; 32(4):1104-6. PubMed ID: 8027323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary antimicrobial susceptibility interpretive criteria for cefetamet (Ro 15-8074) and cefteram (Ro 19-5247) disk tests.
    Jones RN; Barry AL
    J Clin Microbiol; 1987 Sep; 25(9):1796-9. PubMed ID: 3654953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro study with ciprofloxacin: interpretive criteria of agar diffusion test according to standards of the NCCLS and DIN.
    Grimm H
    Am J Med; 1987 Apr; 82(4A):376-80. PubMed ID: 3578326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility testing interpretive criteria and drug stability for cefdinir, cefetamet, and cefpodoxime against Neisseria gonorrhoeae.
    Barrett MS; Jones RN
    Diagn Microbiol Infect Dis; 1992; 15(8):685-91. PubMed ID: 1478049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haemophilus test medium interpretive criteria for disk diffusion susceptibility tests with cefdinir, cefetamet, cefmetazole, cefpodoxime, cefdaloxime (RU29246, HR-916 metabolite), and trospectomycin.
    Jones RN; Erwin ME
    Diagn Microbiol Infect Dis; 1992; 15(8):693-701. PubMed ID: 1478050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interpretive criteria of ceftibuten disk diffusion susceptibility tests according to the DIN 58 940 method.
    Kleinkauf N; Rodloff AC
    Clin Microbiol Infect; 2001 Jun; 7(6):326-30. PubMed ID: 11442566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interpretive criteria of antimicrobial disk susceptibility tests with flomoxef.
    Grimm H
    Infection; 1991; 19 Suppl 5():S258-63. PubMed ID: 1783442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of bacterial susceptibility to cefpodoxime by using the ceftriaxone minimum inhibitory concentration result.
    Jones RN; Zurenko GE
    Diagn Microbiol Infect Dis; 1993; 17(4):313-6. PubMed ID: 8112047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparative antibacterial activity of cefpodoxime against Haemophilus influenzae, Streptococcus pyogenes, Streptococcus pneumoniae and Moraxella catarrhalis].
    Wallrauch-Schwarz C; Milatovic D; Braveny I
    Arzneimittelforschung; 1994 May; 44(5):668-70. PubMed ID: 8024645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of proposed criteria of disk susceptibility testing for tosufloxacin and lomefloxacin in NCCLS guidelines and WHO standards].
    Aihara M; Oguri T; Kanno H; Kubo S; Honda M; Satoh K; Daimon Y; Yamanaka K; Sugawara K; Furuta T
    Rinsho Byori; 1992 Jan; 40(1):73-80. PubMed ID: 1312183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Criteria for the interpretation of sensitivity testing of ofloxacin with the agar diffusion test].
    Grimm H
    Infection; 1986; 14 Suppl 1():S16-9. PubMed ID: 3456982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interpretive criteria for disk diffusion susceptibility testing of sparfloxacin.
    Kayser FH; Wüst J
    Eur J Clin Microbiol Infect Dis; 1991 Mar; 10(3):163-6. PubMed ID: 2060516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Multi-center evaluation of Showa ceftizoxime disk susceptibility test to discriminate between the strains of methicillin-resistant Staphylococcus aureus (MRSA) and those susceptible (MSSA)].
    Moriyasu I; Igari J; Yamane N; Oguri T; Takahashi A; Tosaka M; Takemori K; Toyoshima S; Minamide W
    Rinsho Byori; 1994 Mar; 42(3):271-7. PubMed ID: 8152163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility testing of cefpodoxime.
    Andrews JM; Wise R
    J Antimicrob Chemother; 1991 Oct; 28(4):605-7. PubMed ID: 1761456
    [No Abstract]   [Full Text] [Related]  

  • 16. Correlation of cefpodoxime susceptibility with cephalothin and cefuroxime for urinary tract isolates.
    Bookstaver DA; Bland CM; Woodberry MW; Mansell KB
    J Med Microbiol; 2014 Feb; 63(Pt 2):218-221. PubMed ID: 24214230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interpretive standards for disk susceptibility tests with Sch 21420 and amikacin.
    Barry AL; Thornsberry C; Jones RN; Gerlach EH
    Antimicrob Agents Chemother; 1980 Oct; 18(4):616-21. PubMed ID: 7447420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The correlation between the MICs deduced from Showa disk method and the MICs determined by micro-dilution method].
    Moroizumi S; Kasitani F; Isikawa M; Iwata M; Ohno A; Yamaguchi K
    Rinsho Byori; 1994 Oct; 42(10):1062-8. PubMed ID: 7996716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proposed disk diffusion susceptibility criteria for ofloxacin.
    Fuchs PC; Barry AL; Jones RN; Thornsberry C
    J Clin Microbiol; 1985 Aug; 22(2):310-1. PubMed ID: 3861612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interpretation of susceptibility testing of ceftriaxone.
    Squires E; Cleeland R; Christenson J; Boehni E
    Am J Med; 1984 Oct; 77(4C):12-6. PubMed ID: 6093512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.